By Adria Calatayud

 

Roche Holding said a late-stage trial evaluating its Elevidys drug in Duchenne muscular dystrophy didn't reach its primary goal of showing improvement in a measure of motor function.

The Swiss pharmaceutical giant said late Monday that it will further analyze data from the trial, which evaluated its Elevidys drug in boys aged 4-7 years with Duchenne muscular dystrophy who could walk.

After 52 weeks of treatment, patients showed an improvement of 2.6 points on their North Star Ambulatory Assessment, a measure of motor function, compared to 1.9 points in placebo-treated patients, the company said.

Roche said the trial showed positive efficacy outcomes on functional secondary goals such as time to rise from floor and 10-meter walk test.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

October 31, 2023 02:11 ET (06:11 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.